1887

Abstract

Herein we present evidence for the therapeutic potential of colonization factor (CF)-specific egg yolk antibodies (IgY) for potentially treating acute and recurring infection (CDI) in humans. The study involved cloning, expressing as 6×His-tagged proteins in , and Ni-affinity purifying three previously identified CFs (FliC, FliD and Cwp84) from . The recombinant CF antigens were then used to immunize Leghorn chickens and CF-specific IgY antibodies were prepared from their eggs. The specificity and titre of the resulting CF-specific IgY antibodies were assessed by ELISA and Western immunoblotting techniques. The antibodies were also screened for their ability to inhibit adherence to human colon-derived T84 cells, and, based on these findings, one of them (FliD-specific IgY) was evaluated for its potential to prevent -mediated morbidity and mortality in Syrian hamsters. The results revealed that purified FliD-specific IgY significantly protected hamsters from strain 630 infection relative to control animals treated with carbonate buffer alone or IgY produced from unimmunized chicken eggs. The results suggest that egg yolk preparations obtained from chickens immunized with recombinant CFs may represent another safe and cost-effective treatment option in humans suffering from acute or recurring CDI.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.029835-0
2011-08-01
2021-10-21
Loading full text...

Full text loading...

/deliver/fulltext/jmm/60/8/1181.html?itemId=/content/journal/jmm/10.1099/jmm.0.029835-0&mimeType=html&fmt=ahah

References

  1. Aboudola S., Kotloff K. L., Kyne L., Warny M., Kelly E. C., Sougioultzis S., Giannasca P. J., Monath T. P., Kelly C. P. 2003; Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A. Infect Immun 71:1608–1610 [View Article][PubMed]
    [Google Scholar]
  2. Calabi E., Ward S., Wren B., Paxton T., Panico M., Morris H., Dell A., Dougan G., Fairweather N. 2001; Molecular characterization of the surface layer proteins from Clostridium difficile . Mol Microbiol 40:1187–1199 [View Article][PubMed]
    [Google Scholar]
  3. Calabi E., Calabi F., Phillips A. D., Fairweather N. F. 2002; Binding of Clostridium difficile surface layer proteins to gastrointestinal tissues. Infect Immun 70:5770–5778 [View Article][PubMed]
    [Google Scholar]
  4. Giannasca P. J., Warny M. 2004; Active and passive immunization against Clostridium difficile diarrhea and colitis. Vaccine 22:848–856 [View Article][PubMed]
    [Google Scholar]
  5. Heap J. T., Pennington O. J., Cartman S. T., Carter G. P., Minton N. P. 2007; The ClosTron: a universal gene knock-out system for the genus Clostridium . J Microbiol Methods 70:452–464 [View Article][PubMed]
    [Google Scholar]
  6. Heap J. T., Cartman S. T., Kuehne S. A., Cooksley C., Minton N. P. 2010; ClosTron-targeted mutagenesis. Methods Mol Biol 646:165–182 [View Article][PubMed]
    [Google Scholar]
  7. Hennequin C., Janoir C., Barc M. C., Collignon A., Karjalainen T. 2003; Identification and characterization of a fibronectin-binding protein from Clostridium difficile . Microbiology 149:2779–2787 [View Article][PubMed]
    [Google Scholar]
  8. Job M. L., Jacobs N. F. Jr 1997; Drug-induced Clostridium difficile-associated disease. Drug Saf 17:37–46 [View Article][PubMed]
    [Google Scholar]
  9. Karjalainen T., Barc M. C., Collignon A., Trollé S., Boureau H., Cotte-Laffitte J., Bourlioux P. 1994; Cloning of a genetic determinant from Clostridium difficile involved in adherence to tissue culture cells and mucus. Infect Immun 62:4347–4355[PubMed]
    [Google Scholar]
  10. Karjalainen T., Waligora-Dupriet A. J., Cerquetti M., Spigaglia P., Maggioni A., Mauri P., Mastrantonio P. 2001; Molecular and genomic analysis of genes encoding surface-anchored proteins from Clostridium difficile . Infect Immun 69:3442–3446 [View Article][PubMed]
    [Google Scholar]
  11. Kelly C. P., Pothoulakis C., Vavva F., Castagliuolo I., Bostwick E. F., O’Keane J. C., Keates S., LaMont J. T. 1996; Anti-Clostridium difficile bovine immunoglobulin concentrate inhibits cytotoxicity and enterotoxicity of C. difficile toxins. Antimicrob Agents Chemother 40:373–379[PubMed]
    [Google Scholar]
  12. Kink J. A., Williams J. A. 1998; Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection. Infect Immun 66:2018–2025[PubMed]
    [Google Scholar]
  13. Kirby J. M., Ahern H., Roberts A. K., Kumar V., Freeman Z., Acharya K. R., Shone C. C. 2009; Cwp84, a surface-associated cysteine protease, plays a role in the maturation of the surface layer of Clostridium difficile . J Biol Chem 284:34666–34673 [View Article][PubMed]
    [Google Scholar]
  14. Ko K. Y., Ahn D. U. 2007; Preparation of immunoglobulin Y from egg yolk using ammonium sulfate precipitation and ion exchange chromatography. Poult Sci 86:400–407[PubMed] [CrossRef]
    [Google Scholar]
  15. McFarland L. V. 2009; Renewed interest in a difficult disease: Clostridium difficile infections – epidemiology and current treatment strategies. Curr Opin Gastroenterol 25:24–35 [View Article][PubMed]
    [Google Scholar]
  16. Merrigan M. M., Sambol S. P., Johnson S., Gerding D. N. 2003; Prevention of fatal Clostridium difficile-associated disease during continuous administration of clindamycin in hamsters. J Infect Dis 188:1922–1927 [View Article][PubMed]
    [Google Scholar]
  17. Merrigan M. M., Sambol S. P., Johnson S., Gerding D. N. 2009; New approach to the management of Clostridium difficile infection: colonisation with non-toxigenic C. difficile during daily ampicillin or ceftriaxone administration. Int J Antimicrob Agents 33:Suppl. 1S46–S50 [View Article][PubMed]
    [Google Scholar]
  18. Monaghan T., Boswell T., Mahida Y. R. 2009; Recent advances in Clostridium difficile-associated disease. Postgrad Med J 85:152–162 [View Article][PubMed]
    [Google Scholar]
  19. Mosmann T. 1983; Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55–63 [View Article][PubMed]
    [Google Scholar]
  20. Péchiné S., Gleizes A., Janoir C., Gorges-Kergot R., Barc M. C., Delmée M., Collignon A. 2005; Immunological properties of surface proteins of Clostridium difficile . J Med Microbiol 54:193–196 [View Article][PubMed]
    [Google Scholar]
  21. Sambol S. P., Merrigan M. M., Tang J. K., Johnson S., Gerding D. N. 2002; Colonization for the prevention of Clostridium difficile disease in hamsters. J Infect Dis 186:1781–1789 [View Article][PubMed]
    [Google Scholar]
  22. Savariau-Lacomme M. P., Lebarbier C., Karjalainen T., Collignon A., Janoir C. 2003; Transcription and analysis of polymorphism in a cluster of genes encoding surface-associated proteins of Clostridium difficile . J Bacteriol 185:4461–4470 [View Article][PubMed]
    [Google Scholar]
  23. Tasteyre A., Barc M. C., Karjalainen T., Dodson P., Hyde S., Bourlioux P., Borriello P. 2000; A Clostridium difficile gene encoding flagellin. Microbiology 146:957–966[PubMed]
    [Google Scholar]
  24. Tasteyre A., Barc M. C., Collignon A., Boureau H., Karjalainen T. 2001a; Role of FliC and FliD flagellar proteins of Clostridium difficile in adherence and gut colonization. Infect Immun 69:7937–7940 [View Article][PubMed]
    [Google Scholar]
  25. Tasteyre A., Karjalainen T., Avesani V., Delmée M., Collignon A., Bourlioux P., Barc M. C. 2001b ). Molecular characterization of fliD gene encoding flagellar cap and its expression among Clostridium difficile isolates from different serogroups. J Clin Microbiol 39:1178–1183 [View Article][PubMed]
    [Google Scholar]
  26. Voth D. E., Ballard J. D. 2005; Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev 18:247–263 [View Article][PubMed]
    [Google Scholar]
  27. Warr G. W., Magor K. E., Higgins D. A. 1995; IgY: clues to the origins of modern antibodies. Immunol Today 16:392–398 [View Article][PubMed]
    [Google Scholar]
  28. Weiss K. 2009; Toxin-binding treatment for Clostridium difficile: a review including reports of studies with tolevamer. Int J Antimicrob Agents 33:4–7 [View Article][PubMed]
    [Google Scholar]
  29. Wright A., Wait R., Begum S., Crossett B., Nagy J., Brown K., Fairweather N. 2005; Proteomic analysis of cell surface proteins from Clostridium difficile . Proteomics 5:2443–2452 [View Article][PubMed]
    [Google Scholar]
  30. Wright A., Drudy D., Kyne L., Brown K., Fairweather N. F. 2008; Immunoreactive cell wall proteins of Clostridium difficile identified by human sera. J Med Microbiol 57:750–756 [View Article][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.029835-0
Loading
/content/journal/jmm/10.1099/jmm.0.029835-0
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error